Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
ScripIn a year that has so far been marked by major changes and upheaval at the US Food and Drug Administration, pharma companies are largely still on track with their expected 2025 approvals and launches.
ScripInsmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s
ScripInsmed may be making a best-in-class case in pulmonary arterial hypertension (PAH) for its inhaled powder formulation of treprostinil, the active ingredient in United Therapeutics’ blockbuster Tyvaso.